Vancomycin and Clarithromycin Show Synergy against Mycobacterium abscessus In Vitro

Devika Mukherjee; Mu-Lu Wu; Jeanette W P Teo; Thomas Dick

doi:10.1128/AAC.01298-17

Vancomycin and Clarithromycin Show Synergy against Mycobacterium abscessus In Vitro

Antimicrob Agents Chemother. 2017 Nov 22;61(12):e01298-17. doi: 10.1128/AAC.01298-17. Print 2017 Dec.

Authors

Devika Mukherjee¹, Mu-Lu Wu², Jeanette W P Teo³, Thomas Dick^{4

5}

Affiliations

¹ Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
² Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
³ Department of Laboratory Medicine, National University Hospital, Singapore.
⁴ Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore [email protected].
⁵ Public Health Research Institute, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, New Jersey, USA.

Abstract

Lung disease caused by Mycobacterium abscessus is increasing, and current clarithromycin-based treatment regimens are only moderately effective. Here, we determined the effect of clarithromycin-vancomycin combination against M. abscessus complex isolates in vitro Synergy was found with a fractional inhibitory concentration index (FICI) score of ≤0.5 and a 4- to 10-fold decrease in MIC.

Keywords: Mycobacterium abscessus; clarithromycin; synergy; vancomycin.

MeSH terms

Antibiotics, Antitubercular / pharmacology*
Clarithromycin / pharmacology*
Drug Synergism
Drug Therapy, Combination
Humans
Lung Diseases / drug therapy*
Lung Diseases / microbiology
Microbial Sensitivity Tests
Mycobacterium Infections, Nontuberculous / drug therapy*
Mycobacterium Infections, Nontuberculous / microbiology
Mycobacterium abscessus / drug effects*
Treatment Outcome
Vancomycin / pharmacology*

Substances

Antibiotics, Antitubercular
Vancomycin
Clarithromycin